Comparing BMD-derived genotoxic potency estimations across variants of the transgenic rodent gene mutation assay.
Ontology highlight
ABSTRACT: There is growing interest in quantitative analysis of in vivo genetic toxicity dose-response data, and use of point-of-departure (PoD) metrics such as the benchmark dose (BMD) for human health risk assessment (HHRA). Currently, multiple transgenic rodent (TGR) assay variants, employing different rodent strains and reporter transgenes, are used for the assessment of chemically-induced genotoxic effects in vivo. However, regulatory issues arise when different PoD values (e.g., lower BMD confidence intervals or BMDLs) are obtained for the same compound across different TGR assay variants. This study therefore employed the BMD approach to examine the ability of different TGR variants to yield comparable genotoxic potency estimates. Review of over 2000 dose-response datasets identified suitably
SUBMITTER: Wills JW
PROVIDER: S-EPMC5698699 | biostudies-literature | 2017 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA